Sacha I Rothschild
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Schuler A, Huser J, Schmid S, Schär S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Wannesson L, Pankovics J, Mark M, Rothschild S, Addeo A, Janthur W, Siano M, Boos L, Britschgi C, Früh M. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. Lung Cancer 2023; 187:107427.
22.11.2023Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
22.11.2023Lung Cancer 2023; 187:107427
Schuler Alexandra, Huser J, Schmid Sebastian M, Schär Sämi, Scherz Amina, Gautschi Oliver Pascal, Mauti Laetitia A, von Briel Thomas, Waibel Christine, Wannesson Luciano, Pankovics J, Mark Michael Thomas, Rothschild Sacha I, Addeo Alfredo, Janthur W, Siano Marco, Boos L, Britschgi Christian, Früh Martin
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild S, Hayoz S, Bubendorf L, Özdemir B, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel R, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. J Clin Oncol 2023; 41:5131-5139.
17.08.2023Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
17.08.2023J Clin Oncol 2023; 41:5131-5139
Cathomas Richard, Rothschild Sacha I, Hayoz Stefanie, Bubendorf Lukas, Özdemir Berna C, Kiss Bernhard, Erdmann Andreas, Aeppli Stefanie, Mach Nicolas, Strebel Räto T, Hadaschik Boris, Berthold Dominik R, John Hubert, Zihler Deborah, Schmid Mathias, Alborelli Ilaria, Schneider Martina, Musilova Jana, Spahn Martin, Petrausch Ulf
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Schmitt-Opitz I, Guckenberger M, Früh M, Betticher D, Ris H, Stupp R, Rothschild S, Bubendorf L, Pless M. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. ESMO Open 2023; 8:101595.
11.07.2023Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
11.07.2023ESMO Open 2023; 8:101595
König Dietmar-Pierree, Savic Prince Spasenija, Hayoz Stefanie, Zens P, Berezowska Sabina, Jochum Wolfram, Stauffer Edouard, Braunersreuther V, Trachsel B, Thierstein Sandra, Mark Michael Thomas, Schmid Sebastian M, Curioni-Fontecedro Alessandra, Addeo Alfredo, Schmitt-Opitz Isabelle, Guckenberger Matthias, Früh Martin, Betticher Daniel C, Ris H B, Stupp Roger, Rothschild Sacha I, Bubendorf Lukas, Pless Miklos
The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Seifert B, Alex Kluth L, Ufe M, Mingrone W, Templeton A, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. Eur Urol Open Sci 2023; 50:57-60.
20.02.2023The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
20.02.2023Eur Urol Open Sci 2023; 50:57-60
Fischer Stefanie, Rothermundt Christian, Stalder Odile, Terbuch Angelika, Hermanns Thomas, Zihler Deborah, Müller-Stich Beat P, Fankhauser Christian Daniel, Hirschi-Blickenstorfer Anita, Seifert Bettina, Alex Kluth Luis, Ufe Mark-Peter, Mingrone Walter, Templeton Arnoud J, Fischer Natalie Fischer, Rothschild Sacha I, Woelky Regina, Gillessen Silke, Cathomas Richard
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
Addeo A, Rothschild S, Holer L, Schneider M, Waibel C, Haefliger S, Mark M, Fernandez E, Mach N, Mauti L, Jermann P, Alborelli I, Calgua B, Savic-Prince S, Joerger M, Früh M. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung Cancer 2022; 172:154-159.
28.08.2022Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
28.08.2022Lung Cancer 2022; 172:154-159
Addeo Alfredo, Rothschild Sacha I, Holer Lisa, Schneider Martina, Waibel Christine, Haefliger Simon, Mark Michael, Fernandez Eugenio, Mach Nicolas, Mauti Laetitia, Jermann Philip, Alborelli Ilaria, Calgua Byron, Savic-Prince Spasenija, Joerger Markus, Früh Martin
Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses.
Pratsinis M, Fankhauser C, Pratsinis K, Beyer J, Bührer E, Cathomas R, Fischer N, Hermanns T, Hirschi-Blickenstorfer A, Kamradt J, Alex Kluth L, Zihler D, Mingrone W, Müller B, Nestler T, Rothschild S, Seifert B, Templeton A, Terbuch A, Ufen M, Woelky R, Gillessen S, Rothermundt C. Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. Eur Urol Open Sci 2022; 40:16-18.
26.04.2022Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses.
26.04.2022Eur Urol Open Sci 2022; 40:16-18
Pratsinis Manolis, Fankhauser Christian, Pratsinis Katerina, Beyer Jörg, Bührer Emanuel, Cathomas Richard, Fischer Natalie, Hermanns Thomas, Hirschi-Blickenstorfer Anita, Kamradt Jörn, Alex Kluth Luis, Zihler Deborah, Mingrone Walter, Müller Beat, Nestler Tim, Rothschild Sacha I, Seifert Bettina, Templeton Arnoud J, Terbuch Angelika, Ufen Mark-Peter, Woelky Regina, Gillessen Silke, Rothermundt Christian
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
Furrer K, Weder W, Eboulet E, Betticher D, Pless M, Stupp R, Krueger T, Perentes J, Schmid R, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel R, Rothschild S, Hayoz S, Opitz I. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. J Thorac Cardiovasc Surg 2022; 164:1587-1602.e5.
18.04.2022Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
18.04.2022J Thorac Cardiovasc Surg 2022; 164:1587-1602.e5
Furrer Katarzyna, Weder Walter, Eboulet Eric Innocents, Betticher Daniel, Pless Miklos, Stupp Roger, Krueger Thorsten, Perentes Jean Yannis, Schmid Ralph A, Lardinois Didier, Furrer Markus, Früh Martin, Peters Solange, Curioni-Fontecedro Alessandra, Stahel Rolf A, Rothschild Sacha I, Hayoz Stefanie, Opitz Isabelle
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer.
Bösch M, Baty F, Albrich W, Flatz L, Rodriguez R, Rothschild S, Jörger M, Früh M, Brutsche M. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer. Oncoimmunology 2021; 10:1988403.
10.12.2021Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer.
10.12.2021Oncoimmunology 2021; 10:1988403
Bösch Maximilian, Baty Florent, Albrich Werner, Flatz Lukas, Rodriguez Regulo, Rothschild Sacha I, Jörger Markus, Früh Martin, Brutsche Martin H
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Rothschild S, Cathomas R, Ochsenbein A, Janthur W, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Mark M, Peters S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, Früh M, Jörger M, Lardinois D, Gelpke H, Mauti L, Britschgi C, Weder W, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol 2021; 39:2872-2880.
12.07.2021SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
12.07.2021J Clin Oncol 2021; 39:2872-2880
Rothschild Sacha I, Cathomas Richard, Ochsenbein Adrian F, Janthur Wolf-Dieter, Waibel Christine, Mach Nicolas, Froesch Patrizia, Buess Martin, Bohanes Pierre, Godar Gilles, Rusterholz Corinne, Gonzalez Michel, Pless Miklos, Mark Michael, Peters Solange, Zippelius Alfred, Eboulet Eric I, Savic Prince Spasenija, Betticher Daniel, Bettini Adrienne, Früh Martin, Jörger Markus, Lardinois Didier, Gelpke Hans, Mauti Laetitia A, Britschgi Christian, Weder Walter, Swiss Group for Clinical Cancer Research (SAKK)
Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study
Fuchs J, Früh M, Papachristofilou A, Bubendorf L, Häuptle P, Jost L, Zippelius A, Rothschild S. Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study. PloS one 2021; 16:e0253601.
28.06.2021Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study
28.06.2021PloS one 2021; 16:e0253601
Fuchs Julia, Früh Martin, Papachristofilou Alexandros, Bubendorf Lukas, Häuptle Pirmin, Jost Lorenz, Zippelius Alfred, Rothschild Sacha I
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Froesch P, Früh M, Gautschi O, Sessa C, König D, Metaxas Y, Colombo I, Schmid S, Oppliger Leibundgut E, Rusterholz C, Godar G, Li Q, Rothschild S, Mark M, Swiss Group for Clinical Cancer Research (SAKK). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung Cancer 2021; 156:91-99.
25.04.2021Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
25.04.2021Lung Cancer 2021; 156:91-99
Froesch Patrizia, Früh Martin, Gautschi Oliver, Sessa Cristiana, König David, Metaxas Yannis, Colombo Ilaria, Schmid Sabine, Oppliger Leibundgut Elisabeth, Rusterholz Corinne, Godar Gilles, Li Qiyu, Rothschild Sacha I, Mark Michael, Swiss Group for Clinical Cancer Research (SAKK)
Tumour neoantigen mimicry by microbial species in cancer immunotherapy
Bösch M, Baty F, Rothschild S, Tamm M, Jörger M, Früh M, Brutsche M. Tumour neoantigen mimicry by microbial species in cancer immunotherapy. Br J Cancer 2021; 125:313-323.
06.04.2021Tumour neoantigen mimicry by microbial species in cancer immunotherapy
06.04.2021Br J Cancer 2021; 125:313-323
Bösch Maximilian, Baty Florent, Rothschild Sacha I, Tamm Michael, Jörger Markus, Früh Martin, Brutsche Martin
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Mark M, Früh M, Biaggi-Rudolf C, Weindler S, Baudoux N, Schwitter M, Wannesson L, Jörger M, Metaxas Y, Schneider M, Friedlaender A, Burmeister H, Janthur W, Rothschild S, Pless M, Addeo A, Eboulet E, Froesch P, Swiss Group for Clinical Cancer Research (SAKK). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. Cancer Immunol Immunother 2020
01.11.2020SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
01.11.2020Cancer Immunol Immunother 2020
Mark Michael, Früh Martin, Biaggi-Rudolf Christine, Weindler Susanne, Baudoux Nathalie, Schwitter Michael, Wannesson Luciano, Jörger Markus, Metaxas Yannis, Schneider Martina, Friedlaender Alex, Burmeister Henning, Janthur Wolf-Dieter, Rothschild Sacha I, Pless Miklos, Addeo Alfredo, Eboulet Eric Innocents, Froesch Patrizia, Swiss Group for Clinical Cancer Research (SAKK)
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
Britschgi C, Banna G, Wild P, Rothschild S, Gautschi O, Banini M, Metro G, Früh M, Delaloye R, Rechsteiner M, Addeo A, Curioni-Fontecedro A. Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. Front Oncol 2020; 10:1299.
21.08.2020Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
21.08.2020Front Oncol 2020; 10:1299
Britschgi Christian, Banna Giuseppe L, Wild Peter J, Rothschild Sacha I, Gautschi Oliver, Banini Marco, Metro Giulio, Früh Martin, Delaloye Raphaël, Rechsteiner Markus, Addeo Alfredo, Curioni-Fontecedro Alessandra
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
Schmid S, Jochum W, Addeo A, Demmer I, Schär S, Janthur W, Wannesson L, König D, Britschgi C, Frösch P, Bouchaab H, Rothschild S, Blum V, Friedlaender A, Mauti L, Früh M. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. Cancer Immunol Immunother 2020; 69:1605-1613.
19.04.2020Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
19.04.2020Cancer Immunol Immunother 2020; 69:1605-1613
Schmid Sabine, Jochum Wolfram, Addeo Alfredo, Demmer Izadora, Schär Sämi, Janthur Wolf-Dieter, Wannesson Luciano, König David, Britschgi Christian, Frösch Patrizia, Bouchaab Hasna, Rothschild Sacha I, Blum Veronika, Friedlaender Alex, Mauti Laetitia A, Früh Martin
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC
Schett A, Rothschild S, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Jörger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol 2019; 85:121-131.
19.11.2019Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC
19.11.2019Cancer Chemother Pharmacol 2019; 85:121-131
Schett Anne, Rothschild Sacha I, Curioni-Fontecedro Alessandra, Krähenbühl Stephan, Früh Martin, Schmid S, Driessen Christoph, Jörger Markus
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
Trefny M, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K, Zippelius A, Geier F, Thommen D, Rothschild S, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M, Berner F, Kashyap A, Kaiser M, Herzig P, Poechtrager S, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clin Cancer Res 2019; 25:3026-3034.
14.02.2019A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
14.02.2019Clin Cancer Res 2019; 25:3026-3034
Trefny Marcel P, Savic Spasenija, Jermann Philip, Alborelli Ilaria, Schaub Stefan, Stenner Frank, Früh Martin, Trajanoski Zlatko, Flatz Lukas, Mertz Kirsten D, Zippelius Alfred, Geier Florian, Thommen Daniela S, Rothschild Sacha I, Uhlenbrock Franziska, Rieder Dietmar, Kasenda Benjamin, Stanczak Michal A, Berner Fiamma, Kashyap Abhishek S, Kaiser Monika, Herzig Petra, Poechtrager Severin, Läubli Heinz
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Früh M, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Weder W, Stahel R, Matzinger O, Betticher D, Stupp R, Xyrafas A, Peters S, Ris H, Mirimanoff R, Ochsenbein A, Schmid R, Pless M. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol 2018
26.09.2018Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
26.09.2018J Thorac Oncol 2018
Früh Martin, Guckenberger Matthias, Rothschild Sacha I, Lardinois Didier, Mach Nicholas, Mark Michael, Gautschi Oliver, Thierstein Sandra, Biaggi Rudolf Christine, Weder Walter, Stahel Rolf A, Matzinger Oscar, Betticher Daniel C, Stupp Roger, Xyrafas Alexandros, Peters Solange, Ris Hans Beat, Mirimanoff Rene Olivier, Ochsenbein Adrian F, Schmid Ralph, Pless Miklos
Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)
Rothermundt C, Woelky R, Fankhauser C, Kunit T, Fischer N, Inauen R, Kamradt J, Ziegler K, Haynes A, Jüni P, Grassmugg T, Terbuch A, Thurneisen C, Cathomas R, Müller B, Mingrone W, Hirschi-Blickenstorfer A, Wehrhahn T, Ruf C, Rothschild S, Seifert B, Gillessen Sommer S. Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). Swiss Med Wkly 2018; 148:w14674.
29.08.2018Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)
29.08.2018Swiss Med Wkly 2018; 148:w14674
Rothermundt Christian, Woelky Regina, Fankhauser Christian, Kunit Thomas, Fischer Natalie, Inauen Roman, Kamradt Jörn, Ziegler Katrin, Haynes Alan, Jüni Peter, Grassmugg Thomas, Terbuch Angelika, Thurneisen Claudio, Cathomas Richard, Müller Beat, Mingrone Walter, Hirschi-Blickenstorfer Anita, Wehrhahn Tobias, Ruf Christian, Rothschild Sacha I, Seifert Bettina, Gillessen Sommer Silke
Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland
Sandmeier N, Vogt D, Beyer J, Müller B, von Burg P, Berthold D, Schardt J, Cathomas R, Rothermundt C, Rothschild S, Stenner F. Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland. Clin Genitourin Cancer 2018
02.02.2018Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland
02.02.2018Clin Genitourin Cancer 2018
Sandmeier Nadja, Vogt Deborah R, Beyer Jörg, Müller Beat, von Burg Philippe, Berthold Dominik, Schardt Julian, Cathomas Richard, Rothermundt Christian, Rothschild Sacha I, Stenner Frank